IMBRUVICA 140 mg HARD CAPSULES

Introduction

Package Leaflet: Information for the Patient

IMBRUVICA 140 mg hard capsules

ibrutinib

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.

• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is IMBRUVICA and what is it used for
2. What you need to know before you take IMBRUVICA
3. How to take IMBRUVICA

1. Possible side effects
2. Storage of IMBRUVICA
3. Contents of the pack and further information

1. What is IMBRUVICA and what is it used for

What is IMBRUVICA

IMBRUVICA is a cancer medicine that contains the active substance ibrutinib, which belongs to a class of medicines called kinase inhibitors.

What IMBRUVICA is used for

It is used in adults to treat the following blood cancers:

• Mantle Cell Lymphoma (MCL), a type of cancer that affects the lymph nodes, when the disease has come back or has not responded to treatment.

• Chronic Lymphocytic Leukaemia (CLL), a type of cancer that affects the white blood cells called lymphocytes, which also affects the lymph nodes. IMBRUVICA is used in patients with CLL who have not been previously treated or when the disease has come back or has not responded to treatment.

• Waldenström's Macroglobulinaemia (WM), a type of cancer that affects the white blood cells called lymphocytes. It is used in patients with WM who have not been previously treated or when the disease has come back or has not responded to treatment or in patients for whom chemotherapy given with an antibody is not a suitable treatment.

How IMBRUVICA works

In MCL, CLL, and WM, IMBRUVICA works by blocking Bruton's tyrosine kinase, a protein in the body that helps cancer cells grow and survive. By blocking this protein, IMBRUVICA helps destroy and reduce the number of cancer cells. It may also slow down the worsening of the cancer.

2. What you need to know before you take IMBRUVICA

Do not take IMBRUVICA

• if you are allergic to ibrutinib or any of the other ingredients of this medicine (listed in section 6)
• if you are taking a medicine based on a plant called St. John's Wort or hypericum, used for depression. If you are not sure, consult your doctor, pharmacist, or nurse before taking this medicine.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to take IMBRUVICA:

• if you have ever had unusual bleeding or bleeding at unusual sites or if you are taking any medicines or supplements that increase your risk of bleeding (see section “Using IMBRUVICA with other medicines”)

• if you have had irregular heartbeats, have a history of irregular heartbeats or severe heart failure, or if you feel any of the following: difficulty breathing, weakness, dizziness, fainting, or feeling like you are about to faint, chest pain, or swollen legs

• if you have liver or kidney problems
• if you have high blood pressure
• if you have recently undergone surgery, especially if it has affected the absorption of food or medicines in the stomach or intestine
• if you are going to undergo surgery, your doctor may ask you to stop taking IMBRUVICA for a short period (3 to 7 days) before and after surgery
• if you have had a hepatitis B infection or may have it now. This is because IMBRUVICA may reactivate hepatitis B. Patients will be carefully examined by their doctor for signs of this infection before starting treatment.

If any of the above apply to you (or if you are not sure), consult your doctor, pharmacist, or nurse before taking this medicine.

When taking IMBRUVICA, inform your doctor immediately if you notice or someone notices in you: memory loss, confusion, difficulty walking, or vision loss – these may be due to a rare but serious brain infection (Progressive Multifocal Leukoencephalopathy or PML).

Inform your doctor immediately if you notice or someone observes in you: sudden numbness or weakness of the limbs (especially on one side of the body), sudden confusion, problems speaking or understanding others when they speak to you, loss of vision, difficulty walking, loss of balance, or lack of coordination, severe and sudden headache without a known cause. These may be signs and symptoms of a stroke.

Tests and checks before and during treatment

Tumor Lysis Syndrome (TLS): There have been cases of abnormal levels of chemicals in the blood caused by the rapid breakdown of cancer cells during treatment, and sometimes even without treatment. This can lead to changes in kidney function, abnormal heartbeat, or seizures. Your doctor or other healthcare professional may perform blood tests to check for TLS.

Lymphocytosis: Laboratory tests may show an increase in white blood cells (called "lymphocytes") in your blood during the first few weeks of treatment. This effect is expected and may last for several months. This does not necessarily mean that your blood cancer is getting worse. The doctor will check your blood tests before or during treatment, and in rare cases, may need to administer another medicine. Talk to your doctor about the meaning of the results of these tests.

Children and adolescents

IMBRUVICA should not be used in children or adolescents, as it has not been studied in these age groups.

Other medicines and IMBRUVICA

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription, herbal medicines, and supplements. This is because IMBRUVICA may affect the way other medicines work. Additionally, other medicines may affect the way IMBRUVICA works.

IMBRUVICA may make you bleed more easily.This means you should tell your doctor if you are taking other medicines that increase your risk of bleeding. These include:

• aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen

• anticoagulants such as warfarin, heparin, or other medicines that prevent blood clots
• supplements that may increase your risk of bleeding, such as fish oil, vitamin E, or flaxseed.

If any of the above apply to you (or if you are not sure), consult your doctor, pharmacist, or nurse before taking IMBRUVICA.

Also, inform your doctor if you are taking any of the following medicines: The effects of IMBRUVICA or other medicines may be affected if you take IMBRUVICA together with any of the following medicines:

• medicines called antibiotics to treat bacterial infections: clarithromycin, telithromycin, ciprofloxacin, erythromycin, or rifampicin

• medicines for fungal infections: posaconazole, ketoconazole, itraconazole, fluconazole, or voriconazole

• medicines for HIV infection: ritonavir, cobicistat, indinavir, nelfinavir, saquinavir, amprenavir, atazanavir, or fosamprenavir

• medicines to prevent nausea and vomiting associated with chemotherapy: aprepitant

• medicines for depression: nefazodone

• medicines called kinase inhibitors for the treatment of other cancers: crizotinib or imatinib

• medicines called calcium channel blockers for high blood pressure or chest pain: diltiazem or verapamil

• medicines called statins to treat high cholesterol: rosuvastatin

• medicines for the heart/antiarrhythmics: amiodarone or dronedarone

• medicines to prevent seizures or to treat epilepsy, or medicines to treat a painful condition of the face called trigeminal neuralgia: carbamazepine or phenytoin.

If any of the above apply to you (or if you are not sure), consult your doctor, pharmacist, or nurse before taking IMBRUVICA.

If you are taking digoxin, a medicine used for heart problems, or methotrexate, a medicine used to treat other cancers and to reduce the activity of the immune system (e.g., for rheumatoid arthritis or psoriasis), you should take it at least 6 hours before or after IMBRUVICA.

Using IMBRUVICA with food

Do not take IMBRUVICA with grapefruit or Seville oranges: this means you cannot eat them, drink their juice, or take a supplement that may contain them. This is because they can increase the amount of IMBRUVICA in your blood.

Pregnancy and breastfeeding

You should not become pregnant while taking this medicine. You should not use IMBRUVICA during pregnancy. There is no information on the safety of IMBRUVICA in pregnant women.

Women of childbearing age must use a very effective method of contraception during treatment and for up to 3 months after receiving IMBRUVICA, to avoid becoming pregnant during treatment with IMBRUVICA. If you use hormonal contraceptives, such as pills or contraceptive devices, you should also use a barrier method of contraception (e.g., condoms).

• Tell your doctor immediately if you become pregnant.

• Do not breastfeed while taking this medicine.

Driving and using machines

You may feel tired or dizzy after taking IMBRUVICA, which may affect your ability to drive or use any tools or machines.

IMBRUVICA contains sodium

IMBRUVICA contains less than 1 mmol of sodium (23 mg) per dose; this is essentially “sodium-free”.

3. How to take IMBRUVICA

Follow exactly the instructions of administration of this medicine given by your doctor, pharmacist, or nurse. If you are not sure, consult your doctor, pharmacist, or nurse again.

How much to take

Mantle Cell Lymphoma (MCL)

The recommended dose of IMBRUVICA is four capsules (560 mg) once a day.

Chronic Lymphocytic Leukaemia (CLL)/Waldenström's Macroglobulinaemia (WM)The recommended dose of IMBRUVICA is three capsules (420 mg) once a day.

Your doctor may need to adjust your dose.

How to take IMBRUVICA

• Take the capsules orally (by mouth) with a glass of water.

• Take the capsules at approximately the same time every day.

• Swallow the capsules whole. Do not open, break, or chew the capsules.

If you take more IMBRUVICA than you should

If you take more IMBRUVICA than you should, consult your doctor or go to the hospital immediately.

Bring the capsules and this leaflet with you.

If you forget to take IMBRUVICA

• If you forget a dose, you can take it as soon as possible on the same day and return to your normal schedule the next day.

• Do not take a double dose to make up for a forgotten dose.

• If you are not sure, talk to your doctor, pharmacist, or nurse about when to take your next dose.

If you stop taking IMBRUVICA

Do not stop taking this medicine unless your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may occur with this medicine:

Stop taking IMBRUVICA and tell your doctor immediately if you experience any of the following side effects:

rash with blisters and itching, difficulty breathing, swelling of the face, lips, tongue, or throat: you may be having an allergic reaction to the medicine.

Tell your doctor immediately if you experience any of the following side effects:

Very common(may affect more than 1 in 10 people)

• fever, chills, body pain, feeling tired, cold or flu symptoms, difficulty breathing: all these can be symptoms of an infection (caused by a virus, bacteria, or fungus). They can include infections of the nose, sinuses, or throat (upper respiratory tract infections), or of the lungs, or of the skin.

• bruises or increased tendency to bruise

• mouth sores

• headache

• constipation

• feeling or being sick (nausea or vomiting)

• diarrhea, your doctor may need to give you treatment to replace fluids and salts or another medicine

• rash

• pain in arms or legs

• back pain or joint pain

• muscle cramps, muscle pain, or muscle spasms

• low number of cells that help blood to clot (platelets), very low number of white blood cells: shown in blood tests

• swollen hands, ankles, or feet

• high blood pressure

Common(may affect up to 1 in 10 people)

• severe infections that spread throughout the body (septicemia)

• urinary tract infections

• nosebleeds, small red or purple spots on the skin caused by bleeding under the skin

• bleeding in the stomach, intestine, stools, or urine, increased bleeding during menstruation, or bleeding from a wound that cannot be stopped

• increased heart rate, missing heartbeats, weak or irregular pulse, dizziness, difficulty breathing, discomfort in the chest (symptoms of heart rhythm disorders)

• increased number or proportion of white blood cells in the blood

• low white blood cell count with fever (febrile neutropenia)

• abnormal levels of chemicals in the blood, produced by the rapid breakdown of cancer cells during treatment, and sometimes even without treatment (tumor lysis syndrome)

• skin cancer other than melanoma, most frequently basal cell carcinoma and squamous cell carcinoma

• feeling dizzy

• blurred vision

• redness of the skin

high levels of “uric acid” in the blood (shown in blood tests), which can cause gout

• inflammation of the airways (pulmonary) that can lead to permanent damage

• breaking of the nails

• weakness, numbness, tingling, or pain in the hands or feet or other parts of the body (peripheral neuropathy)

Uncommon(may affect up to 1 in 100 people)

• liver failure

• severe fungal infections

• confusion, headache with problems speaking or feeling like you are about to faint: these can be symptoms of a severe internal bleeding in the brain

• allergic reaction, sometimes severe, which can include swelling of the face, lip, mouth, tongue, or throat, difficulty swallowing or breathing, rash with itching (urticaria)

• inflammation of the fatty tissue under the skin

• transient episode of neurological dysfunction caused by loss of blood flow, stroke

Rare(may affect up to 1 in 1,000 people)

• severe increase in the number of white blood cells that can cause cells to clump together

Not known(frequency cannot be estimated from the available data)

• severe skin rash with blisters and peeling of the skin, particularly around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of IMBRUVICA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the label of the bottle after EXP. The expiry date is the last day of the month shown.

No special storage conditions are required.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

Composition of IMBRUVICA

• The active ingredient is ibrutinib. Each hard capsule contains 140 mg of ibrutinib.

• The other components are:

• capsule content: sodium croscarmellose, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate (E487)
• capsule shell: gelatin and titanium dioxide (E171)
• printing ink: shellac, iron oxide black (E172), and propylene glycol (E1520).

Product Appearance and Container Content

IMBRUVICA is presented in hard, opaque white capsules marked with "ibr 140 mg" in black ink on one side.

The capsules are supplied in a plastic bottle with a child-resistant polypropylene closure. Each bottle contains 90 or 120 capsules. Each container contains one bottle.

Marketing Authorization Holder

Janssen-Cilag International NV

Turnhoutseweg 30

B-2340 Beerse

Belgium

Manufacturer

Janssen Pharmaceutica NV

Turnhoutseweg 30

B-2340 Beerse

Belgium

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:

Date of the Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.